Nanoscope Therapeutics to Detail Gene Therapy Path in Boston
The company will discuss regulatory and clinical trial pathways at the Advanced Therapies USA 2026 conference this November.
Updated on Oct. 31, 2026 in Biotech
Live Poll
Are new gene therapies for blindness moving toward public availability quickly enough?
Nanoscope Therapeutics leadership will address clinical and regulatory pathways for optogenetic therapies at the Advanced Therapies USA 2026 conference in Boston on November 4-5, 2026. The company is currently navigating FDA and PMDA review for its MOGENRY gene therapy.
Why it matters
As Nanoscope moves toward a planned 2026 Phase 3 registrational trial, the company's participation highlights the logistical and regulatory hurdles required to transition complex optogenetic treatments from successful clinical trials to market access.
Nanoscope is developing MOGENRY, an optogenetic gene therapy, having previously completed a Phase 2b/3 trial for retinitis pigmentosa. The company is now preparing for a 2026 Phase 3 registrational trial and a separate Phase 2 program for geographic atrophy.
The players
Nanoscope Therapeutics
A Dallas-based biotechnology firm focused on developing optogenetic gene therapies for retinal degeneration.
The details
MOGENRY is an optogenetic gene therapy, a method that uses light-sensitive proteins to restore vision by making non-photoreceptor cells in the retina responsive to light. This approach aims to treat retinal degeneration by re-sensitizing retinal cells after traditional photoreceptors have lost function. The company is presenting these scientific pathways at the conference while simultaneously pursuing FDA and PMDA regulatory reviews for the therapy.
Timeline
November 4, 2026: Nanoscope leadership begins presenting at the Hynes Convention Center in Boston.
November 5, 2026: The final day of Nanoscope leadership panels and presentations in Boston.
The Tech Race
Nanoscope is currently advancing through the regulatory environment after securing FDA Fast Track and Orphan Drug designations for its lead therapy. The company remains in competition with other developers of gene-based blindness treatments as it prepares to initiate pivotal Phase 3 testing.
Patients and clinicians in the Boston area will gain insight into the clinical trajectory of MOGENRY during the upcoming industry conference. While the technology is currently in regulatory review, the upcoming trials will clarify the potential timeline for broader patient access to these optogenetic therapies.
The takeaway
Nanoscope is transitioning its focus from clinical trial completion to the complexities of commercial and market access pathways. Observers should track the company's 2026 Phase 3 trial initiation as a key indicator of its progress toward regulatory approval.
What happens next
Nanoscope Therapeutics plans to initiate a Phase 3 registrational trial for MOGENRY and a Phase 2 program for geographic atrophy in 2026.
Further reading
For more on the emerging landscape of gene-based vision treatments, see Biotech.
Live Poll
Are new gene therapies for blindness moving toward public availability quickly enough?
